Your browser is no longer supported. Please, upgrade your browser.
Settings
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E86.93 EPS (ttm)0.47 Insider Own0.20% Shs Outstand2.44B Perf Week-1.72%
Market Cap100.35B Forward P/E14.63 EPS next Y2.81 Insider Trans0.00% Shs Float2.44B Perf Month-2.81%
Income1.17B PEG6.35 EPS next Q- Inst Own9.20% Short Float0.23% Perf Quarter7.13%
Sales35.63B P/S2.82 EPS this Y-89.20% Inst Trans0.20% Short Ratio1.80 Perf Half Y1.83%
Book/sh0.59 P/B69.69 EPS next Y4.19% ROA1.60% Target Price47.00 Perf Year0.36%
Cash/sh2.61 P/C15.75 EPS next 5Y13.70% ROE78.60% 52W Range36.69 - 43.93 Perf YTD8.28%
Dividend2.00 P/FCF- EPS past 5Y-28.90% ROI8.60% 52W High-6.39% Beta0.98
Dividend %4.86% Quick Ratio0.60 Sales past 5Y0.40% Gross Margin68.10% 52W Low12.09% ATR0.37
Employees99827 Current Ratio0.90 Sales Q/Q20.70% Oper. Margin9.30% RSI (14)41.43 Volatility0.69% 0.76%
OptionableYes Debt/Eq16.72 EPS Q/Q171.00% Profit Margin3.30% Rel Volume0.97 Prev Close40.78
ShortableYes LT Debt/Eq13.04 EarningsMay 03 Payout426.60% Avg Volume3.17M Price41.12
Recom2.00 SMA20-1.61% SMA50-0.90% SMA2001.27% Volume3,075,534 Change0.83%
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
Apr-24-17 12:30PM  First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus American City Business Journals
Apr-22-17 12:03PM  3 Dividend Stocks That Retirees Should Avoid Motley Fool
Apr-21-17 04:52PM  Barclays -- Mired In Mud (Again) -- Should Dump Its CEO Forbes
01:13PM  Analyst Estimates for Novartiss 1Q17 Earnings Market Realist
11:21AM  What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings? Zacks
07:07AM  4 Stocks Are Showing Red Flags -- Here's When to Sell TheStreet.com
12:00AM  $3M award in suit against drug company over man's suicide Associated Press
Apr-20-17 06:43PM  Teva's new asthma inhaler poses first competition for GSK's Advair Reuters
06:08PM  Here's Why Innoviva Inc. Lost 10% Today Motley Fool
05:38PM  GSK must pay $3 million in generic Paxil suicide lawsuit: U.S. jury Reuters
05:32PM  GSK must pay $3 mln in generic Paxil suicide lawsuit: U.S. jury Reuters
02:35PM  As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy Benzinga
01:34PM  Teva launches copy of asthma inhaler Advair Reuters
09:42AM  Innoviva director vote drama hands last-minute loss to Sarissa Reuters
12:30AM  ZappRX gets $25 million from Qiming US to expand into the U.S. drug prescription market TechCrunch
Apr-19-17 10:09PM  Activist Sarissa says Innoviva backed out of proxy settlement deal Reuters
Apr-18-17 09:39PM  There Have Been Few Losers Since The Brexit Vote, But It's About To Get Ugly Forbes
07:15PM  [$$] Science looks to nucleic acids to create right genetic vaccine recipe Financial Times
08:15AM  Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology Accesswire
Apr-17-17 10:43AM  OncoMed's lung cancer drug fails mid-stage study, shares tumble Reuters
Apr-13-17 05:35PM  Innoviva to review costs, executive pay following Sarissa pressure Reuters
Apr-12-17 08:04AM  This Survey's Bad News Could Be Good News for Inovio Pharmaceuticals, Inc. Motley Fool
Apr-11-17 06:15AM  Hearing loss biotech Frequency Therapeutics dials up $32M round American City Business Journals
06:00AM  The State of Play in Axovant Sciences Investopedia
Apr-09-17 03:03PM  The 3 Best HIV Drug Stocks to Buy in 2017 Motley Fool
Apr-08-17 12:03PM  GlaxoSmithKline Dodges a Bullet... for Now Motley Fool
07:22AM  3 Big Pharma Companies With the Best Pipelines Motley Fool
Apr-06-17 09:41AM  4 Big Reasons Mylan N.V. Shares Fell 7% in March Motley Fool
05:00AM  Just How Much Is a Medical Miracle Worth? Bloomberg
Apr-05-17 04:21PM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline Motley Fool
02:49PM  At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims TheStreet.com
08:50AM  GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S. TheStreet.com
Apr-03-17 04:11PM  GlaxoSmithKline Initiates Phase III Study with Mepolizumab Zacks
09:06AM  Novartis Expects to Witness Flat Revenue Growth in 2017
08:25AM  Wall Street Loves European Stocks: 5 Top Dividend Picks to Buy Now 24/7 Wall St.
07:36AM  How Eli Lillys New Products Performed in 2016
Apr-02-17 12:18PM  [$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D at The Wall Street Journal
Apr-01-17 08:45AM  50 Advertisers Boycott YouTube Advertising, And It Won't Mean More Than A 1% Dip In Google's Top Line Benzinga
06:41AM  The Worst-Case Scenario for Gilead Sciences, Inc. Motley Fool
12:08AM  [$$] Glaxos New CEO Is a Steady Hand in Pharmaceuticals Rolling Seas The Wall Street Journal
Mar-31-17 03:29PM  Understanding Sanofis Valuation Compared to Peers Market Realist
07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
Mar-30-17 10:36AM  What Wall Street Analysts Estimate for GlaxoSmithKline Market Realist
09:06AM  GlaxoSmithKlines Consumer Healthcare Segment in 2016
07:36AM  Performance of GlaxoSmithKlines Vaccines Business in 2016
03:44AM  GSK's new CEO gets short-term win from generic Advair delay Reuters
Mar-29-17 04:01PM  VBI Vaccines Emerges as Strong Biotech Stock
03:00PM  GlaxoSmithKline Continues to Strengthen
02:04PM  Mylan stock sinks 2% after FDA fails to approve its generic asthma medication at MarketWatch
01:27PM  U.S. FDA rejects Mylan's generic version of GSK's Advair Reuters
11:49AM  GlaxoSmithKline Advair May Escape Generics Challenge at Investopedia
10:36AM  Performance of GlaxoSmithKlines HIV Business in 2016
09:06AM  Performance of Key Pharmaceuticals Products for GlaxoSmithKline
07:37AM  GlaxoSmithKlines Pharmaceuticals Segment Performance
12:21AM  [$$] FDA Nominee Scott Gottlieb Plans Recusals From Decisions on Many Drug Firms at The Wall Street Journal
12:01AM  [$$] FDA Nominee Plans Recusals From Decisions on Many Drug Firms at The Wall Street Journal
Mar-28-17 11:34AM  GlaxoSmithKline Plc : GSK-US: Dividend Analysis : February 24th, 2017 (record date) : By the numbers : March 28, 2017
10:39AM  GlaxoSmithKlines Segment-Wise Performance in 2016
09:08AM  Performance of GlaxoSmithKline in 2016
07:37AM  GlaxoSmithKlines Valuation Compared to Its Peers
Mar-27-17 08:44PM  First Trump Hiccups, Now Brexit Flare-Ups Coming For Stocks at Forbes
10:27AM  J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
Mar-24-17 05:52PM  Coca-Cola, Walmart Latest to Pull Ads From Google Amid Concerns About Offensive Content at TheStreet
05:05PM  Exploring Novartiss 2016 Revenue
11:29AM  Why Google Has to Definitively Address Its Offensive Content Problem
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
Mar-23-17 01:04PM  GLAXOSMITHKLINE PLC Financials
07:21AM  Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Reuters
Mar-22-17 08:01PM  GSK and Regeneron to mine gene data from 500,000 Britons
10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017
09:06AM  Xifaxan Expected to Witness Robust Growth in 2017
Mar-21-17 02:58PM  Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
02:13PM  Still Bullish on GlaxoSmithKline
12:13PM  7 Pharma Plays With Emerging Market Potential at Barrons.com
09:18AM  6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar-20-17 06:22PM  Novartis (NVS) Announces Positive Data on Heart Failure Drug
10:32AM  AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
Mar-17-17 09:45AM  AstraZeneca Inks $230 Million COPD Drugs Deal at Investopedia
07:38AM  A Look at Opdivos Performance in 2016
Mar-16-17 12:00PM  Glaxo Seeks Label Expansion for Fluarix Vaccine at Investopedia
08:59AM  Glaxo Files for Label Expansion of Influenza Vaccine in US
Mar-15-17 12:07PM  GSK: New Female CEO Gets 25% Less Than Predecessor at Investopedia
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
11:13AM  GSK announces US regulatory submission seeking expanded indication for Fluarix® Quadrivalent (Influenza Vaccine) for infants 6 months and older PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines
05:45AM  Once paid by Vertex, Trump's FDA pick would be tasked with regulating it at bizjournals.com
Mar-14-17 03:23PM  Top Research Reports for Intel, Schwab & Glaxo
11:38AM  Couple sue pharma giant for work that led to prison in China
11:12AM  How a Major Drugmaker Plans to Cure Disease... Without Drugs at Motley Fool
10:29AM  Glaxo to Pay First Woman CEO Less, Cites Lack of Experience
09:28AM  Its time to vaccinate your investments against a deadly bird flu at MarketWatch
Mar-10-17 10:30AM  Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
09:21AM  Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
Mar-09-17 02:35PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
11:02AM  Gilead: "Stuck Between A Rock And A Hard Place?" at Barrons.com
08:49AM  Coverage initiated on GlaxoSmithKline by Kepler and Liberum
Mar-08-17 10:35AM  Trump rally on pause: Stocks, Dow Jones sluggish despite strong ADP jobs report: Snap, Goldman, BofA, Urban Outfitters on the move at bizjournals.com
Mar-07-17 04:21PM  Novartis (NVS) Reports Positive Data on Biosimilar Humira
04:08PM  GlaxoSmithKline's Nucala Positive in Label Expansion Study
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV, as well as oncology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM